[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334129-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334129-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-genome-wide-crispr-screen-reveals-that-hoxa9-promotes-enzalutamide-resistance-in-prostate-cancer","A Genome Wide CRISPR Screen Reveals That HOXA9 Promotes Enzalutamide Resistance in Prostate Cancer","","Androgen receptor inhibitors are widely used for prostate cancer, yet acquired resistance limits long-term benefit. A study performed a genome-wide CRISPR knockout screen in LNCaP cells to identify gene loss events affecting response to enzalutamide. Losses that increase enzalutamide sensitivity highlighted pathways tied to stem cell and epigenetic regulation. HOXA9 was evaluated as a candidate: genomic datasets linked HOXA9 overexpression with poor prognosis and advanced disease features. In culture, HOXA9 depletion enhanced enzalutamide sensitivity, while HOXA9 overexpression promoted resistance. Combining the HOXA9 inhibitor DB818 with enzalutamide showed synergistic effects, supporting new therapeutic directions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-genome-wide-crispr-screen-reveals-that-hoxa9-promotes-enzalutamide-resistance-in-prostate-cancer/334129/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-genome-wide-crispr-screen-reveals-that-hoxa9-promotes-enzalutamide-resistance-in-prostate-cancer/334129.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is enzalutamide resistance a major issue in prostate cancer?","Question",{"text":63,"@type":64},"Enzalutamide improves outcomes in castration-resistant prostate cancer, but many patients later develop resistance. This progression leads to a more aggressive, hard-to-treat disease stage.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What approach was used to identify genes influencing enzalutamide response?",{"text":68,"@type":64},"A genome-wide CRISPR knockout screen was conducted in LNCaP prostate cancer cells. The screen mapped gene loss events that confer either resistance or sensitivity to enzalutamide.",{"name":70,"@type":61,"acceptedAnswer":71},"How does HOXA9 affect sensitivity to enzalutamide?",{"text":72,"@type":64},"HOXA9 overexpression correlated with poor prognosis and advanced prostate cancer features. In cell culture, HOXA9 depletion sensitized cells to enzalutamide, whereas HOXA9 overexpression drove enzalutamide resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334129,1790174049,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","MOLECULAR AND CELLULAR BIOLOGY 2024, VOL. 44, NO. 12, 529–542  \n[https://doi.org/10.1080/10985549.2024.2401465](https://doi.org/10.1080/10985549.2024.2401465)  \nA Genome Wide CRISPR Screen Reveals That HOXA9 Promotes Enzalutamide Resistance in Prostate Cancer  \nMichael V. Roesa, b,c and Frederick A. Dicka, b,c  \naDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario,  \nCanada; bLondon Regional Cancer Program, London, Ontario, Canada; cLondon Health Sciences Research Institute, London, Ontario, Canada  \nABSTRACT  \nAndrogen receptor inhibitors are commonly used for prostate cancer treatment, but acquired resistance is a significant problem. Codeletion of RB and p53 is common in castration resistant prostate cancers, however they are difficult to target pharmacologically. To comprehensively identify gene loss events that contribute to enzalutamide response, we performed a genome-wide CRISPR knockout screen in LNCaP prostate cancer cells. This revealed novel genes implicated in resistance that are largely unstudied. Gene loss events that confer enzalutamide sensitivity are enriched for GSEA categories related to stem cell and epigenetic regulation. We investigated the myeloid lineage stem cell factor HOXA9 as a candidate gene whose loss promotes sensitivity to enzalutamide. Cancer genomic data reveals that HOXA9 overexpression correlates with poor prognosis and characteristics of advanced prostate cancer. In cell culture, HOXA9 depletion sensitizes cells to enzalutamide, whereas overexpression drives enzalutamide resistance. Combination of the HOXA9 inhibitor DB818 with enzalutamide demonstrates synergy. This demonstrates the utility of our CRISPR screen data in discovering new approaches for treating enzalutamide resistant prostate cancer.  \nARTICLE HISTORY  \nReceived 10 January 2024 Revised 5 August 2024 Accepted 19 August 2024  \nKEYWORDS  \nProstate cancer; therapy resistance; lineage plasticity; stemness  \nIntroduction  \nProstate cancer is one of the most commonly diagnosed cancers among men and a leading cause of cancer-related deaths.1 In the majority of cases, prostate cancer is an androgen dependent disease that is driven through the androgen receptor signaling pathway.2–4 First line therapy for recurrent prostate cancer patients acts to deplete hormones through androgen deprivation.3 However, some patients develop castration-resistant prostate cancer, in which disease progresses in a low androgen environment.5 Second-generation AR inhibitors, such as enzalutamide, have led to improved patient outcomes for castration resistant prostate cancer.6, 7 However, these benefits are often short lived as patients develop resistance and enter a fatal stage.8  \nAn increasingly recognized mechanism of resistance to enzalutamide in castration resistant disease occurs through lineage plasticity or acquisition of a neuroendocrine fate.8–11 In this resistance scenario, an adenocarcinoma alters its lineage under the selective pressure of enzalutamide to a new fate that no longer expresses or needs the androgen receptor for proliferation.8 Treatment induced neuroendocrine prostate cancer is a clinically aggressive disease characterized by RB and p53 loss, low AR signaling and increased expression of neuroendocrine markers such as chromogranin A (CHGA),  \nsynaptophysin (SYP) and neuron specific enolase (NSE) .8, 11 Quite commonly seen in clinical biopsies are mixed adenocarcinoma and neuroendocrine tumors that is indicative of lineage plasticity where cells are uncommitted a specific lineage.12 These patients are often treated with platinum-based chemotherapies but have dismal survival rates of about 24 months.13 This has led to an intense search for drivers of treatment induced neuroendocrine prostate cancer that has identified MYCN,14 SOX2,15 SOX9,16 FOXA1,17 ONECUT2, 18 BRN2,19 and PEG10,20 among others. Unfortunately, only NMyc regulation of EZH2 has thus far presen","cbCaio2vBrNwBAwt","https://ap.wps.com/l/cbCaio2vBrNwBAwt","pdf",2362610,14,"English","# Introduction\n## Androgen receptor signaling and enzalutamide resistance\n## Lineage plasticity and neuroendocrine prostate cancer\n## HOXA9 background and therapeutic resistance gap\n# Methods and Study Rationale\n## Genome-wide CRISPR knockout screen in LNCaP cells\n# Key Findings\n## Gene loss events linked to enzalutamide sensitivity\n## HOXA9 as a functional candidate\n## HOXA9 depletion vs overexpression effects\n## DB818 and enzalutamide synergy","[{\"question\":\"Why is enzalutamide resistance a major issue in prostate cancer?\",\"answer\":\"Enzalutamide improves outcomes in castration-resistant prostate cancer, but many patients later develop resistance. This progression leads to a more aggressive, hard-to-treat disease stage.\"},{\"question\":\"What approach was used to identify genes influencing enzalutamide response?\",\"answer\":\"A genome-wide CRISPR knockout screen was conducted in LNCaP prostate cancer cells. The screen mapped gene loss events that confer either resistance or sensitivity to enzalutamide.\"},{\"question\":\"How does HOXA9 affect sensitivity to enzalutamide?\",\"answer\":\"HOXA9 overexpression correlated with poor prognosis and advanced prostate cancer features. In cell culture, HOXA9 depletion sensitized cells to enzalutamide, whereas HOXA9 overexpression drove enzalutamide resistance.\"}]","A Genome Wide CRISPR Screen Reveals That HOXA9 Promotes Enzalutamide Resistance in Prostate Cancer | PDF",1790005419,35]